New Approaches for Functional Oligonucleotides: RNA Activation and Non-Nucleosidic Aptamers.
Date: November 20, 2025 Time: 11-12pm EST / 5-6pm CET Title: New Approaches for Functional Oligonucleotides: RNA Activation and Non-Nucleosidic Aptamers Description: This talk will highlight two complementary approaches aimed at expanding the functional scope of oligonucleotide therapeutics. First, I will present ...
DNA-based tools for the study and treatment of Parkinson’s Disease
Date: November 6, 2025 Time: 11-12pm EST / 5-6pm CET Title: DNA-based tools for the study and treatment of Parkinson’s Disease Description: Aptamers are short stretches of DNA that fold into 3-dimensional shapes that can act as pockets for binding other ...
Financing the Future of Individualized Medicine: Funding Models for Rare Genetic Therapies
Date: September 18, 2025 Time: 11-12pm EDT / 5-6pm CEST Title:Financing the Future of Individualized Medicine: Funding Models for Rare Genetic Therapies Description: Individualized medicine has emerged as an approach offering bespoke therapeutics to patients with rare genetic conditions. In spite ...
From Discovery to Deals: The Neurological Oligonucleotide Landscape at a Glance
Date: September 4, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: From Discovery to Deals: The Neurological Oligonucleotide Landscape at a Glance Description: A deep dive on the drug landscape, displaying critical data-driven therapeutic and clinical trial highlights, as well as ...
Strategic IP for Oligonucleotide Therapeutics: Maximizing Innovation Value
Date: August 28, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: Strategic IP for Oligonucleotide Therapeutics: Maximizing Innovation Value Description: This talk will explore the essential elements of an effective IP strategy tailored for oligonucleotide therapeutics, balancing scientific innovation with commercial ...
The importance of involving patients in therapy development; Lessons learned from Duchenne exon skipping
Date: August 21, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: The importance of involving patients in therapy development; Lessons learned from Duchenne exon skipping Description: Duchenne muscular dystrophy is a progressive muscle wasting disease caused by lack of dystrophin protein. ...
Perspectives on Oligonucleotide Therapeutics: A discussion with Rebecca Miles, incoming president of OTS
Date: June 12, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: Perspectives on Oligonucleotide Therapeutics: A discussion with Rebecca Miles, incoming president of OTS Presentation Description: In this interview, Dr. Rebecca Miles, the president-elect of the Oligonucleotide Therapeutics Society, will discuss ...
Trainee Spotlight Series: Poster Winners #OTS24 Session 5
Date: May 15, 2025 Time: 11-12pm EDT / 5-6pm CEST Join us for this Trainee Spotlight webinar featuring trainee Daniel van Leeuwen, poster award winner at the 2024 OTS Annual Meeting. Title: Deciphering the impact of toxic antisense oligonucleotide (ASO) ...
Trainee Spotlight Series: Poster Winners #OTS24 Session 4
Date: April 10, 2025 Time: 11am EDT / 5pm CEST Join us for the fourth Trainee Spotlight webinar of the year featuring trainees Faith Kivunga, Atish Wagh Ph.D, and Svenja Dudek, poster awards winners from the 2024 OTS Annual Meeting held last fall. ...
Meet Your New BOD Trainee Reps
Date: March 27, 2025 Time: 12pm EDT / 5pm CET Title: Developing Oligonucleotides to Modulate HTT mRNA isoforms Presentation Description: Huntington’s Disease is an autosomal dominant neurodegenerative disease caused by an expanded CAG repeat tract within exon 1 of the Huntingtin ...
